Morgan Stanley 13D and 13G filings for Arbutus Biopharma Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-03 3:26 pm Purchase | 2024-12-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 21,524,661 11.400% | 2,132,173 (+10.99%) | Filing |
| 2024-06-10 4:50 pm Purchase | 2024-05-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 19,392,488 10.300% | 17,954,224 (+1248.33%) | Filing |
| 2021-02-10 12:13 pm Sale | 2020-12-31 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 1,438,264 1.700% | -2,059,314 (-58.88%) | Filing |
| 2020-07-16 4:22 pm Purchase | 2020-07-07 | 13G | Arbutus Biopharma Corporation ABUS | MORGAN STANLEY MS | 3,497,578 5.100% | 3,497,578 (New Position) | Filing |